Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Solriamfetol in Shift work disorder. The expected timing is based on the latest available company guidance and may change.
SUSTAIN trial. 8/5/24- Trial initiated. 5/5/25- Topline results in 2026. 11/30/25:- Topline results from the SUSTAIN Ph3 SWD trial remain anticipated in 2026. 02/23/26:- SUSTAIN Phase 3 shift work disorder trial topline results timeline updated; now anticipated in 2027. 05/04/26:- SUSTAIN Phase 3 shift work disorder trial ongoing; topline results continue to be anticipated in 2027.
Verification
Confirm timing and program details against the company announcement or filing.